Home » Regions » Asia » WuXi PharmaTech goes private

WuXi PharmaTech goes private

Monday, August 17, 2015

WuXi PharmaTech has entered into a merger agreement with New WuXi Life Science and WuXi Merger, a wholly owned subsidiary of Parent.

Parent will acquire the company for cash consideration equal to $5.75 per ordinary share of the company and $46 per American Depositary Share (ADS) of the company, each representing eight shares, or about $3.3 billion in aggregate cash consideration. That figure represents a 16.5% premium over the closing price of $39.50 per ADS as quoted by the New York Stock Exchange on April 29, and a premium of 18.9% and 20.1%, respectively, over the company’s 30- and 60- trading day volume-weighted average price as quoted by the NYSE prior to April 29, 2015, the last trading day prior to the company’s announcement on April 30 that it had received a non-binding “going private” proposal.

Immediately following the consummation of the transactions contemplated by the merger agreement, Parent will be beneficially owned by a consortium comprised of:

  • New investors including affiliates of or funds managed or advised by Ally Bridge Group Capital Partners, Boyu Capital, Temasek Life Sciences Private and Ping An Insurance;
  • Hillhouse Fund II, an existing shareholder of the company and an affiliate of Hillhouse Capital; and
  • Founders and executive officers of the company who have elected to roll-over their interest in the company in connection with the merger including Dr. Ge Li, the chairman and chief executive officer; Xiaozhong Liu, an executive vice president and a director; Zhaohui Zhang, a senior vice president of operations, the head of domestic marketing and a director; and Dr. Ning Zhao, a senior vice president of operations, the head of corporate human resources and a director.

The merger, which is expected to close during the fourth quarter of 2015, is subject to shareholder approval as well as certain other customary closing conditions.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!